GEM3-PSCA

N/A

Report date: 2026/03/19 16:59:40

Base Information

Drug NameGEM3-PSCA
Drug Alias NameGEM3-PSCA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-PSCA
TargetsT cell surface glycoprotein CD3Prostate stem cell antigen
Therapy Area/IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGemoab MonoconalsGcp Service International
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvenCell Europe GmbHBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksN/A